VYNE Therapeutics Inc. (VYNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
VYNE POWR Grades
- VYNE scores best on the Growth dimension, with a Growth rank ahead of 95.63% of US stocks.
- VYNE's strongest trending metric is Value; it's been moving up over the last 52 weeks.
- VYNE ranks lowest in Momentum; there it ranks in the 8th percentile.
VYNE Stock Summary
- With a year-over-year growth in debt of -97.01%, VYNE Therapeutics Inc's debt growth rate surpasses merely 1.83% of about US stocks.
- The volatility of VYNE Therapeutics Inc's share price is greater than that of 99.18% US stocks with at least 200 days of trading history.
- VYNE Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -148.72%, greater than the shareholder yield of just 1.52% of stocks in our set.
- Stocks that are quantitatively similar to VYNE, based on their financial statements, market capitalization, and price volatility, are AMST, FLDM, NURO, AMSC, and AGE.
- Visit VYNE's SEC page to see the company's official filings. To visit the company's web site, go to www.menlotherapeutics.com.
VYNE Valuation Summary
- VYNE's EV/EBIT ratio is -0.2; this is 100.68% lower than that of the median Healthcare stock.
- Over the past 44 months, VYNE's price/sales ratio has gone down 907.3.
- Over the past 44 months, VYNE's price/sales ratio has gone down 907.3.
Below are key valuation metrics over time for VYNE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VYNE | 2021-08-31 | 5.5 | 1.2 | -1.0 | -0.2 |
| VYNE | 2021-08-30 | 5.5 | 1.2 | -1.0 | -0.2 |
| VYNE | 2021-08-27 | 5.3 | 1.1 | -1.0 | -0.2 |
| VYNE | 2021-08-26 | 4.9 | 1.0 | -0.9 | -0.1 |
| VYNE | 2021-08-25 | 5.1 | 1.1 | -0.9 | -0.1 |
| VYNE | 2021-08-24 | 5.1 | 1.1 | -0.9 | -0.1 |
VYNE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VYNE has a Quality Grade of D, ranking ahead of 14.91% of graded US stocks.
- VYNE's asset turnover comes in at 0.132 -- ranking 235th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows VYNE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.132 | 0.856 | -2.324 |
| 2021-03-31 | 0.194 | 0.926 | -5.086 |
| 2020-12-31 | 0.170 | 0.934 | -4.672 |
| 2020-09-30 | 0.140 | 0.949 | -4.901 |
| 2020-06-30 | 0.115 | 0.964 | -4.606 |
| 2020-03-31 | 0.016 | 0.845 | -1.853 |
VYNE Price Target
For more insight on analysts targets of VYNE, see our VYNE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.00 | Average Broker Recommendation | 1.58 (Moderate Buy) |
VYNE Stock Price Chart Interactive Chart >
VYNE Price/Volume Stats
| Current price | $1.00 | 52-week high | $13.20 |
| Prev. close | $1.03 | 52-week low | $0.98 |
| Day low | $0.98 | Volume | 629,338 |
| Day high | $1.05 | Avg. volume | 1,250,533 |
| 50-day MA | $1.28 | Dividend yield | N/A |
| 200-day MA | $3.53 | Market Cap | 53.52M |
VYNE Therapeutics Inc. (VYNE) Company Bio
VYNE Therapeutics Inc. operates as a clinical stage bio-pharmaceutical company. The Company develops medicines and therapies for the treatment of chronic pruritus and cough. VYNE Therapeutics serves customers worldwide.
Latest VYNE News From Around the Web
Below are the latest news stories about VYNE Therapeutics Inc that investors may wish to consider to help them evaluate VYNE as an investment opportunity.
VYNE Therapeutics (NASDAQ:VYNE) investors are sitting on a loss of 80% if they invested a year agoThe art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But... |
VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business UpdateLead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sale of Topical Minocycline Franchise Continues to Advance Conference call and Live Webcast Today at 8:30 am Eastern Time BRIDGEWATER, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announce |
Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical StudyResults support continued progression of VYN201 development program for autoimmune skin diseasesBRIDGEWATER, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced preclinical data from a validated animal study showing that its bromodomain and extra-terminal (“BET”) inhibitor, VYN201, demonstrated improvements in reducing fibrotic tissue mass and overall skin repair outcomes with no negative impact on healing time. VYNE is evaluati |
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseVYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details:Wednesday, November 10th @ 8:30am Eastern TimeToll Free:855 |
VYNE Price Returns
| 1-mo | -25.37% |
| 3-mo | -41.18% |
| 6-mo | -74.75% |
| 1-year | -85.47% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -84.18% |
| 2020 | -65.95% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...